featured
news articles

Total number of categories

Total number of articles

Market/Novel Tech

Alkahest’s oral small molecule drug aims to report on a Phase IIa study for age-related macular degeneration

Alkahest Inc., a clinical stage biopharmaceutical company based in San Carlos, California, has announced that an experimental drug, AKST4290, in a Phase IIa study for AMD, showed that  83% of patients maintained or improved their visual acuity, and 21% of patients gained at least 15 letters in BCVA. The open-label Hungarian trial enrolled 29 patients […]

Read full story
Featured

Clinical research for systematic reviews and meta-analysis focuses on cn-AMD, DMO, RVO-MO and m-CNV

A systematic review and meta-analysis, published by British Medical Journal Open (2019), has included 19 randomized controlled trials (RCTs) to evaluate the comparative effectiveness and safety of intravitreal bevacizumab (Avastin), ranibizumab (Lucentis) and aflibercept (Eylea) for patients with cn-AMD, DMO, RVO-MO and m-CNV.  According to the study review, intravitreal bevacizumab was as effective as ranibizumab […]

Read full story
Research

A drug delivery approach for a thermoresponsive polymer shows sustained anti-VEGF treatment for AMD

Researchers in an independent Australian federal research agency (CSIRO), Victoria, Australia, have demonstrated that a novel polymer synthesizing two anti-VEGF treatments (bevacizumab and aflibercept) may be used to extend drug delivery release profiles over a 183 day period.  As anti-VEGF intravitreal injections generally require burdensome monthly treatments, the new reverse thermoresponsive polymer (RTP) may significantly […]

Read full story
Introduction

June 17th, 2019: “EURETINA-Brief”© Issue No. 194

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the June 17th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]

Read full story
Research

Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data

Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides a real-world setting, albeit different to the outcome data reported from clinical trial publications. In follow-up to real-world 5-year outcome data on a retrospective population, the results indicate that a […]

Read full story
Introduction

April 16th, 2019: “EURETINA-Brief” Issue No. 190

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]

Read full story

Latest News

Book Review